Immunotherapies News and Research RSS Feed - Immunotherapies News and Research

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences. [More]
Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. [More]
Researchers explore ways to use light to combat cancer

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals. [More]
Immunotherapy could be the future of cancer treatments

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." [More]
OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. [More]
New Georgia Tech research center launched to manufacture living cells for cell-based therapies

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies. [More]
MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina. [More]
Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. [More]
Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies. [More]
F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed. [More]
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. [More]
New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours. [More]
SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Shells of plant virus trigger immune system to wipe out tumors, provide protection against metastases

Shells of plant virus trigger immune system to wipe out tumors, provide protection against metastases

The shells of a common plant virus, inhaled into a lung tumor or injected into ovarian, colon or breast tumors, not only triggered the immune system in mice to wipe out the tumors, but provided systemic protection against metastases, researchers from Case Western Reserve University and Dartmouth University report. [More]
Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

The first Toulouse Onco Week (TOW) is due to take place from 3 to 6 February 2016 at the Pierre Baudis Congess Center, Toulouse, France. This unique event will be focused on the international fight against cancer by bringing together stakeholders from around the world and presenting the latest global innovations in oncology. [More]
RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore. [More]
OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016. [More]
New injectable 'biogel' may become new weapon against cancer

New injectable 'biogel' may become new weapon against cancer

A new injectable "biogel" is effective in delivering anti-cancer agents directly into cancerous tumours and killing them. This technology, developed by researchers at the University of Montreal Hospital Research Centre, has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer. [More]
AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. [More]
Possible reasons found for Alzheimer’s treatment failure

Possible reasons found for Alzheimer’s treatment failure

Agglutinated proteins in the brain, known as amyloid-β plaques, are a key characteristic of Alzheimer’s. One treatment option uses special antibodies to break down these plaques. [More]
Advertisement
Advertisement